Updated: Dec 3, 2021
OPEN INVITATION - Details below - Every Wednesday
Link to call Wednesday December 1st starting at 7:00-8:30 pm Central time
Note: This itinerary will be updated between now and start of call with speakers and their discussions, aiming to allot 10-20 mins per person. Depending on how many people actually show up we may open the floor at the end, just whatever is right for the vibe.
I will also make sure to record this call and leave it here after we conclude our discussion. Feel free to record it as well. (Transcript is on the very bottom of page for those who want to check it out)
Recorded call here, audio is what it is, but content is good. Next week, Ill have a bit better method:
[Title of your discussion] - [When you will speak - 7:00-7:15 pm]
[your name or nickname] [A link to where someone can find you]
If you want a picture or two for your reference and aid in discussion you can send it over to me via email email@example.com, or send it via twitter, I'll make sure to get it on here and make it look pretty.
Also, just send a short summary of what you will talk about, or bullet points.
To recap what I need from you to send to me via email or twitter:
Title of discussion
Link or place you'd prefer people to find you
Pictures or charts (not needed but if you want)
Bullet points of your discussion so listeners can follow along. If they'd like.
Introduction & Succinct Overview of Progenity's Products 7:15-7:30 pm
Brad Mitchell Optifinancialnews.com
OBDS | DDS | PIL DX
15% bio with inital product- 2022 - PK/PD data December PK/PD <- watch
JetCap comparison (they claim 50% bioavailability!!!) - compares and illustrates jet stream
Competition Overview (Look at Rani) 1.4 Billion as of writing, Prog valued at .44 Billion
Topics/Pictures from and submissions from the community (will update more if you send me after the call)
Research and findings from Mr Good Advisor Twitter - (@ChrisMaster700)
William Sandborne - a board member who is the leader in GI tract diseases has multiple connections to Pfizer, Abbvie (which are the rumoured partners/suitors) :
Pictures of screenshots below:
Pfizer connections of the Progenity Board member:
Progidity - "The Tesla of biotech"
All right. Hey there guys. I'm going to wait probably a minute or two into that, into the space to get it going here. So I was planning on getting a recording on my desktop, but it looks like Twitter doesn't have that functionality yet to, control the space meeting from the desktop. So what I'm going to do is recorded, but it won't be very good quality.
So after the meeting, if someone actually, if someone has that capability to do it, then if you could please record it and send it to me. No problem though. I will have a recording. It just won't be great audio. So, so, you know, there is a link to my website or blog kind of with all the information and like kind of talking points.
I initially wanted to see if we could get some people on to, you know, send info over to me. We didn't get anybody cause there's such short notice. So what I'm going to plan to do is do this weekly on just virginity. So company that I'm pretty passionate about and it's something that I can definitely see being a weekly event.
And I know Wednesday nights are not always typically great for people. So appreciate you guys being here in the first place. And I know today was kind of a tough day if you were holding stock, but I think this company is undervalued and fundamentally it needs to be re-evaluated. So with that you can find more on that, on my profile with the kind of like temporary it is being changed a little bit.
I'm going to update it after the call. And after I get done speaking, what I'll do is open up the floor to everybody. So with that said let's begin. So obviously you've probably invested, or you're looking at investing in this company and I just want to give you an introduction to who I am and where I come from and just kind of my background.
So just to disclaimer everything said here is not financial advice and is for entertainment only. I'm just, you know, speaking what my opinion is and just want to lay that out first. So. A little bit more about me. My name is Bradley Mitchell and I I'm an optical and mechanical engineer. I work in like clean rooms with lasers and advanced concepts in technologies.
I've seen quite a bit of technology kind of go through in my experience. I'm also surrounded by quite a few health professionals and get feedback from them as well on topics such as virginity. And I've gotten some really good feedback and helped me understand certain topics of virginity.
Another fun fact about me is I'm a type one diabetic, and I've actually been through a research study. I think it was a phase one, a research study on a drug for diabetes when I was first diagnosed in sixth grade. So what's some of those things I've just been really interested in, you know, technology and medical devices, you know, I live with medical devices and it's something I'm pretty close to and have an understanding of what works and what a patient might want, what a doctor might want.
And so after, you know, searching around and having this blog out for about a year, I've been just. Mess, you know, writing about virginity or sorry, not presented, but other companies and you know, calling price targets and things of that nature. I want to say when I came to virginity, what I saw and why I invested initially is the efficacy and safety increases of the, you know, of the pill, what it could actually do for the human or the you know, the healthcare industry and how it can disrupt that platform.
So just again, for those who are joining one just mentioned to you that there is a link to itinerary, just some like photos and topics. If you guys want to like message me either on Twitter or at my email, go ahead. I will update the itinerary and blog with your extra due diligence research.
Thoughts and opinions on what I think could be really valuable for people who are coming in or just people who just want to, you know, reestablish their conviction with this company. So today I'm going to talk about a few things and then I'm going to open up the floor for discussion. Should probably take me hopefully 30 minutes.
I'm gonna try to be, you know, succinct with what I'm talking about. So today I'm going to be talking about the three. Products in the pipeline that I believe will make Progenity a multi-billion dollar company. And the reasons why that will be why they can be at multi-billion dollar company kinda quick, you know, seed in competition, like their comp competitors within that talk.
And then I'm going to also talk about, you know, why virginity fell so hard. Why is it at $2 a share if it's going to be this multi-billion dollar company and LP, really talk about, you know, value and. Cache there's so many other factors that are, that are at play, but I'm just going to cover the fundamentals in the value.
There's some, there's some plenty, there are plenty people out there who have come from, you know, GME and, you know, short squeeze era and they have, they're much more experts than I am at that, you know, technical charting. I think true demon would be a great reference to go to. There's some others as well.
Just listening to him. Also K Thomas he's a good guy to go to on Twitter kind of, you know, he's logical and, you know, keeps, he keeps things fair and honest. So then I'm going to, after you're already talking about the survivor role, I'm going to go with some price targets that I'm forecasting, obviously that can be different from what you think, or, you know, there's just my opinions on, you know, what I see in this company now versus like other companies that are now $60 billion, like Dexcom or tandem diabetes, those medical bills.
Companies that came from like two bucks to all the way up to Dexcom, like two weeks ago at six 50. So I'm just going to talk about that and then open the floor up. So with that being said let's talk about the oral biological deliveries. Oh, God system. I think that's what it's called the OBDs.
So this, this is the pill that virginity is focusing on and has come to focus on as being one of the top hitters or the top value producers. And it's the technology. I think they need to do a better job at describing to investors and to the market. They really haven't shown how it works, which which I think is another reason why this company is kind of not been looked at very much.
They only have preclinical studies done over it. Nonetheless I'll just dive into it now. So the OBDs works by a liquid jet. So what they do, the pill is taken by the patient and the PA and the pill goes down into the targeted area of the digestive track. What they're targeting is most likely the small intestines, which is the highest uptake zone in your digestive track.
And so what this does is it at that certain spot after it detects where it's at by using its three LEDs and a sensor and machine learning, it essentially turns on a pressure releases, a pressure valve, and then jets out the, the drug liquid drug into the sides of the intestine. Now the pressure is probably Attuned to the one, like a water pick out a dentist.
That's probably the pressure that you're going to need to get the drug past the mucus layer into the, the capillary beds of the intestines. So that's really the fundamental difference between, you know, just a drug that people take. It can instead it can bypass the large intestine or excuse me, small intestines, a mucosal layer and get large molecules through before there has been really no other option.
There has been studies done on the OBDs technology. Similar competition, muco jet and jet cat. If you look at my itinerary, you'll see some jet cap it's like a red and a yellow pill kind of shows you that process and how they use a spring. But really the deepest part of virginity is they have the ability to locate anywhere in the, in, in the GI track.
They don't, and we're, I'm waiting for an extra study in 2022, which will really, really prove the value of Progenity is when they show the OBDs and fasting state and non-fasting state. So when they show the device working and. People who haven't eaten versus people who have eaten. And if they can show that they have precision with this pill, for people who are just eating eaten and have food in their system, it will be very critical.
And it will show the value of the company as cause because as from the patient standpoint, it's going to be something you're willing to take and you're going to be compliant with it. So some other applications for the OBDs would be long lasting insulin. And the reason long lasting insulin is a.
A thing that OBDs could use is recently the cost of insulin have come down substantially. So before oral insulin has not been applied to the GI tract because it was just so expensive, but because costs of insulin are coming down. Now you can use the larger volumes of insulin to basically get into the GI tract.
And especially with the ODS jet stream technology getting 15% or more bioavailability bioavailability will be a groundbreaking in that industry. Especially because this tech pill can also send a signal. To like your iPhone or your, you know, Google phone, whatever you use. And that can be used to be sent over to the doctor.
So the doctor can see a compliance and then the patient can also get the feedback that, oh, my pill did release and it didn't, you know, cut out on me. That's a big bonus to the comp competition factor. A lot of these technologies haven't demonstrated or have not had the patents that show the, their technology is transmitting information from the gut to a phone.
I mean, that, that feedback is very, very critical and that's kind of why Dexcom right now is doing very well in the industry. For diabetes, they use a transmitter on the patient's skin. Tells the blood sugar to the patient sends that info to the phone and the doctors get it, the patient, get it. And it's a very helpful tool and taking care of your health.
So for long lasting insulin, that's a great thing. It's a big market. I think there'll BDS has potential and that is just like small, like a very small list of the ODS. You know, you have other drugs and I've been talking and I'm verifying with a scientist right now about the CRISPR technologies and how viable that method would be.
There's no studies on it, but I just want to plant that in there because right now, virginity hasn't announced it nobody's announced it, but that technology if capable that that's a game changer in the future. So that's just another thing to look at. Let's see, I guess I'll move on from the OBDs the JetStream.
To the DDS, which is kind of like a, it's the same pill, but it doesn't use the JetStream. It essentially uses a low pressure gas to release drug over a certain period of time. So the DDS is being used with AbbVie right now, or excuse me, I apologize. It's being used with AbbVie's drug add Illuma MAB, or you could call it Humira.
And essentially what it does is it lines the whole, the colon. So after it passes all of the intestines, it re it can recognize, oh, Hey, I'm now into the large intestines. Now I'm going to turn on and release this drug. So they've shown Pfizer's two faceted. To have 25 times to 40 times more effective it, excuse me, not effectively, but more drug on the target location site.
This means that the patients with ulcerative colitis or excuse me, I'm blanking on the other one. The other there's two main ones shown that th that higher dosage of drug on the location site is much better than when you're taking a shot because, or like an IV or a sub subcutaneous injection.
So, Right now, when you take an injection, you get only like a very small amount of the drug to the, the treatment site. But with virginity, you can get the drug with high dosage and low, like low amounts of the drug in the system in the systemic basically reduces the systemic risk to a patient, which is very important.
I think that's why you're getting these large pharmas like Ionis you know, possibly Pfizer AbbVie or Nova Nordisk. All of those large pharmas could possibly be interested in the OBDs technology, sorry, I'm switching back to the jet stream tech because they can have increased bio availability.
Gosh, it can not speak. And what that does is. Less drug more effectively. And you know, at the end of the day, that's what you want. So one other thing on the AbbVie relationship with adilumumab you, they have a patent expiration on their drug currently on Humira Humira. And you know, this is like an $18 billion industry, and it's one of the top selling large molecule drugs ever to be sold.
That patent is expiring. believe 20, 22, 20 23. You don't fact, you know, fact check me on that, but very, very soon, and that that's going to be very important for virginity because they can actually extend the value and efficacy. For Humira. And I could see AbbVie, you know, offering a partnership and I hopefully hoping that they don't get bought out because I can see, you know virginity doing much better with partnerships.
Okay. So I'm going to move from the OB dis to DDS that, and then now I'm finishing off with the P I L D X or pill DX. And it's, you know, P I L stands for virginity ingestible lab diagnostics. And so this one is actually pretty critical. It's a, a point of care pill, which means essentially that, you know, you go into your primary care provider, like, you know, the doctor's office, right.
And so you've got something going on with your gut. You don't, you have a stomach bug or, you know, something of that nature. Well, instead of the doctor guessing giving you some antibiotics, you know, they can initially just give you the pill to yet. And within, you know, two hours that pill can pass through, it can diagnose different molecules and you'll see that Virginia, you just got a patent and granted actually in China for this type of tech like a secret, you know, looking at different strands of DNA, which can, you know, be biomarkers.
And then once the pill gets the data, it sends it out to the doctor and will most likely be processed by software giving the doctor, Hey, this is probably what they have. Then the doctor can more effectively treat. So you know, all of these things have a lot of value and, you know, I can't, you can do basic napkin math.
And it just, I mean, it's very, very interesting to see that the stock is still point, you know, four or $5 billion or the company is worth. When the leading the other competitor, which is rainy therapeutics you'll also see on the itinerary itinerary. I put a thing about rainy on there. You can click the link and it'll show you who rainy is and what they do is just very easy to see that, you know, virginity is worth more than rainy theory therapeutics, and I'm not trying to, you know, dog, any companies.
I think it's great what they're doing. However see the the problems, stumbling block, stumbling blocks and problems with rainy therapeutics technology. So it's just really interesting to see that, you know, rainy is multiplied three times, Progenity, which is very odd, but that is what it is right now.
So we may be getting the stock at a very cheap and discounted rate, especially today with that large draw, it was very hard to watch. If you have, you know, short-term expectations. I still do believe in December, we will see a substantial appreciation just due to the I'll find, you know, I'll finish out here just due to the PK PD data.
We'll be coming out for the DDS, which is the the, the, the capsule that releases over time in the colon, which treats ulcerative colitis and I'm blanking on the other one. I think it's IBD or can look it up our quarters letting me, so regardless that PKPD data basically shows, Hey, does this pill actually work?
And if it shows, does shows the efficacy and the ability to treat this'll make Progenity a more interesting partner for AbbVie or Pfizer or any of the large farmers that are trying to get, you know, increase the efficacy or safety of their drugs. So be watching out for that December data release.
That should be a pretty big catalyst for virginity. And I think I have kinda finished up here a little early from, you know, what I wrote down. I have, you know, if you have questions, please ask just kind of wanted to give you as much as I could in a short amount of time. And thanks. And I'll, I'll see if anybody would like to talk now, just raise your hand or if you want to be a speaker or just ask a question.
I think I could definitely give you an answer or, you know, maybe that'd be an action point for me.
Let's see, I got a request here. Hey, Ivanka. Okay, great. I'm about to accept you in. Alrighty. You can speak.
Hey, thank you very much. How's it going? Hey, it's going pretty good. I appreciate you tenants. Seriously. This is amazing to have all these people here and just kind of being having everyone so passionate about the company that we think has a good future. Yeah, for sure, man. It's been quite a ride, huh?
Having the space. I appreciate it. So I'm just a little curious about like the manufacturing costs behind the technology, like the pill you're describing. Do you know anything about that? Yeah, absolutely. I've got some pretty good background just for my engineering side. So the manufacturing process, once they get it up and going.
You're looking at LEDs, which are a light emitting diodes, very inexpensive, extremely inexpensive. The sensor, which is a, probably a photo sensor is also extremely sensitive. You can act ex inexpensive. I apologize. Those are kind of there you know, the transmitters and receivers, then you've got your, like your circuit card assembly, which they all connect to.
Those are very cheap. If you look online, big circuit cards, well, I know there's a chip shortage, but a big circuit cards, you know, you can make 10 of them for like, you know, $2 just custom fit boards. And then obviously the plastics and things of that nature once all put together, you know, the pill can be made, you know, each pill can probably be made for less than $10 if you're making millions of them.
So if you sell that pill for. For a hundred dollars or $2,000. Actually a Dexcom sensors are worth $1,500 base costs and then insurance pays for it because they know the future benefit. So if Progenity is to use this, they could probably, you know, make a range from 1500 or sell the pills for 1500 down to a hundred dollars a pill, and then insurance would cover the rest.
So that's a great question, actually. That is very interesting because each pill has its different manufacturing processes. So like the OBDs for instance, has. Pressurized gas, if you believe it's into its very inert gas, or basically a gas that, you know, doesn't, it doesn't touch anything or, you know, it doesn't interact.
So they'll have to pressurize it through a quick probably machine, just quick boom, pressurized to a certain tune pressure. And then it'll just pass through. So a lot of things are so small, which makes the, you know, you know, once you commit, you know, perfect the equipment that makes the pill, I don't see the cost being too much for each pill.
Yeah, that's a good question. And you know what, I think I should do a deeper dive on that as I, you know, walk through it every week. So thanks for that question. That's that's really good. Thank you very much for the answer. That was definitely. I was worried that manufacturing cost might be a big hurdle, but it sounds like it wouldn't be too bad.
Thank you very much. Yeah, absolutely. Most of the stuff like the injection molding, most of the parts will be injection molded. It's very common. So like, you know, forks, spoons, you know, all that stuff is so cheap to make. And I know that sounds weird, but I want the pill, the I, the pill part is just, it's like the IP is the most important part, which virginity obviously has 200 patents in queue.
They, I think they have 180 or so already, you know, gone through Yeah, definitely. That was a great question. Something I hadn't thought too deep on, so yeah, there's like so many stones to unturn and I hope that for us in these conversations to get to those, because that's, you know, if I can't answer it now or we can't answer it now, maybe we go back and do do some research on it and then come back to the answer.
And if it changes our fundamental, you know, thoughts on the business, then, you know, that's when we rethink things or, you know, so I really appreciate that. So thanks. If you have any more, please, please do that is really on the technical aspect. Yeah, that's really good. And not everyone knows this, but I actually applied to Progenity as a, you know, a technical lead there.
So if I do get that role, I may have to, you know, I'll stop, but I'll let everyone know that You know, hired on to make it work, so,
yeah, right on yeah, if anyone's got any thoughts or just feelings on, you know, how today was, or like regarding like even a short squeeze hypothesis, I know there's some really good, you know, thoughts on there. I just haven't you know, dove into that, that technical aspect of the company. But I do know that they have cash.
And honestly one big thing that we may do, we may have not realized we have probably turned around this company because of our, you know, investments. I know they may be, some people may be investing more, less than others, but presumably has had the opportunity through us to become a $60 billion business.
So I think for me, my 10 to 12 year outlook for virginity is, you know $400 a share. And that's just from comparing other companies like virginity at the early stage of development, such as Dexcom. And that's, you know, seeing the relationships between the two actually funny piece of info on Dexcom is virginity and Dexcom actually used the same engineering consultants to build some of their products.
So the DDS Lancer prototype the one that is going to get the PK PD data. This December we'll have has actually been worked on by Novo engineer. Which actually helped develop some, a Dexcom's applicators and stuff like that. So kinda, kind of cool to see that presented he's using reliable companies and things of that nature for their tech pills.
Yeah. Anyone feel free to just poke out. Doesn't have to be long. It can be thoughts or things like that. So let me get a recorder. I got another request here. Awesome. Tonks for stocks. Hey there it looks to me like you're connecting right now. So give you a second city, a city shrimp. I will get you on in a second.
Stay mood, stay muted while tonks for stocks interested, tries to join in and unmute.
Hello? Can you hear me? Yep. Okay, fantastic. I'm trying to formulate my questions. So just give me a minute, but it has to do with the PKP D data. And so I kind of was getting into it with someone on Twitter here just a second ago, they had a screenshot. I think this is from the earnings report meeting that they had right back in like November 10th.
And so it looks like someone was asking a question about when the upcoming PKP D data would right. Be dropped. And they're asking ADI this question and he says you know, give me a couple of weeks. You know, he's essentially only been there for a few days at that point. It's like, just give me a couple of weeks.
I essentially am interpreting this as to get my feet wet, to sort of see where things are at because as the individual also asks. You know what ADI thoughts were on timing of future design and clinical trials. So one of my questions is how in what form is this data is supposed to be released. Like typically it's going to be in some sort of publication because bio pharma, biotech companies are working in the labs, all sorts of labs, institutional labs, and university labs, and those scholars and those researchers that are doing that research work.
And I know this is also with So it also would depend, I guess, on which labs Abby's doing work and which researchers that they're funding. So there's a lot of people involved and people who have careers at stake that need to be published. Usually data has to be acknowledged in order to protect it.
Right. So they know if they're planning on releasing this more as a corporate presentation on their site, which would seem a little odd to me because there was some mention, I guess, in the screenshot of it's still under review. And when I hear that, because I am a napkin daytime among other things, and it happened out of and I work for an academic journal.
I might think about para and friends that are also genetic researchers, right. That do a lot of publishing. So when you hear a peer review, I mean, there's, there's pairing, you comes in at so many different points of research. One of it it's just, you have right. Literally peers reviewing the data like right there in the lab.